New UK firm raises funds to transform chemotherapy into targeted chemotherapy
This article was originally published in Scrip
Executive Summary
UK-based biopharmaceutical company NuCana BioMed has raised £6.74 million series A venture financing round led by Sofinnova Partners and joined by Morningside Ventures, Scottish Investment Bank's Scottish Venture Fund and Alida Capital International.